FPF
JUNO

FNY Partners Fund’s Juno Therapeutics, Inc. JUNO Stock Holding History

FNY Partners Fund’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,500
Closed -$33K – 1406
2017
Q1 		$33K Buy
+1,500
New +$32.2K ﹤0.01% 835

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FNY Partners Fund's JUNO Position: Q2 2017 in Review

FNY Partners Fund sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2017, closing a stake of 1,500 shares — an estimated $33K sold.

FNY Partners Fund first reported a position in JUNO in Q1 2017 and held it in 1 quarter. The position peaked at $33K in Q1 2017. 173 funds tracked by Wall St. Rank hold JUNO as of Q2 2017.

  • FNY Partners Fund reported no remaining Juno Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • FNY Partners Fund sold 1,500 Juno Therapeutics, Inc. shares in Q2 2017, an estimated $33K.
  • FNY Partners Fund first reported a position in Juno Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • FNY Partners Fund's Juno Therapeutics, Inc. position peaked at $33K in Q1 2017.
  • 173 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2017.

Based on FNY Partners Fund's 13F filing for Q2 2017, filed 10 Aug 2017.